All the news Showing 10 of 36 articles from: Treatment in liver transplantedGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation Liz Highleyman / 08 December 2014 An interferon-free regimen of sofosbuvir plus ledipasvir (Harvoni) taken with ribavirin for 12 or 24 weeks led to sustained virological response in nearly all HCV genotype 1patients with fibrosis or less-advanced liver cirrhosis, researchers ... People living with HIV have high survival rates after liver transplants due to HCC Keith Alcorn / 12 November 2014 People with HIV – most of whom had hepatitis B or C co-infection – generally had good outcomes after liver transplantation due to hepatocellular carcinoma (HCC), with five-year survival rates similar to those ... Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation Liz Highleyman / 29 May 2014 An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to ... Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence Keith Alcorn / 23 April 2014 A three-drug combination of direct-acting antivirals developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant recipients with recurrent hepatitis C in a small phase II study reported at ... Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease Liz Highleyman / 17 April 2014 Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and people who experience severe hepatitis ... European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection Gilead press release / 17 January 2014 Sofosbuvir taken before or after liver transplant reduces hepatitis C recurrence Liz Highleyman / 08 November 2013 An interferon-free combination of sofosbuvir plus ribavirin administered before liver transplantation prevented hepatitis C recurrence in nearly two-thirds of patients, while the same regimen led to early viral clearance in three-quarters of those ... Immunosuppression, EVR predictive of SVR in liver transplant recipients with HCV Healio Hepatology / 08 November 2013 Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation Gilead press release / 03 November 2013 Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant Henry Ford Health System press release / 01 November 2013 ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive